As of the latest Form 4 filed Jun 17, 2026.
What BioXcel Therapeutics Inc insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
Buys plotted up, sells down; bar height is the disclosed dollar value (shares × reported price). Our Form 4 history is only complete from mid-2026, so early months are sparse — the series fills in as more filings land. Open-market purchases and sales only.
Newest filing first — the 24 most recent filings for BTAI.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-06-17 | 2026-06-15 | Rodriguez Javier See Remarks | MExercise | +35.00 | — | — | No | Form 4 ↗ |
| 2026-06-17 | 2026-06-15 | Steinhart Richard I Chief Financial Officer | MExercise | +35.00 | — | — | No | Form 4 ↗ |
| 2026-06-17 | 2026-06-15 | Yocca Frank Chief Scientific Officer | MExercise | +35.00 | — | — | No | Form 4 ↗ |
| 2026-06-17 | 2026-06-15 | Mehta Vimal CEO and President | MExercise | +219.00 | — | — | No | Form 4 ↗ |
| 2026-05-22 | 2026-05-20 | Yocca Frank Chief Scientific Officer | SSale | −6.84K | $1.09 | $7.43K | Yes (planned) | Form 4 ↗ |
| 2026-05-22 | 2026-05-20 | Rodriguez Javier See Remarks | SSale | −6.56K | $1.08 | $7.11K | Yes (planned) | Form 4 ↗ |
| 2026-05-22 | 2026-05-20 | Steinhart Richard I Chief Financial Officer | SSale | −6.84K | $1.09 | $7.43K | Yes (planned) | Form 4 ↗ |
| 2026-05-22 | 2026-05-20 | Mehta Vimal CEO and President | SSale | −19.4K | $1.09 | $21.1K | Yes (planned) | Form 4 ↗ |
| 2026-05-22 | 2026-05-04 | Yocca Frank Chief Scientific Officer | MExercise | +17.5K | — | — | Yes (planned) | Form 4 ↗ |
| 2026-05-22 | 2026-05-04 | Rodriguez Javier See Remarks | MExercise | +17.5K | — | — | Yes (planned) | Form 4 ↗ |
| 2026-05-22 | 2026-05-04 | Steinhart Richard I Chief Financial Officer | MExercise | +17.5K | — | — | Yes (planned) | Form 4 ↗ |
| 2026-05-22 | 2026-05-04 | Mehta Vimal CEO and President | MExercise | +49.8K | — | — | Yes (planned) | Form 4 ↗ |
| 2026-05-07 | 2026-05-01 | Mehta Vimal CEO and President | MExercise | +18.0K | — | — | No | Form 4 ↗ |
| 2026-05-07 | 2026-05-01 | Steinhart Richard I Chief Financial Officer | MExercise | +9.00K | — | — | No | Form 4 ↗ |
| 2026-05-07 | 2026-05-01 | Yocca Frank Chief Scientific Officer | MExercise | +9.00K | — | — | No | Form 4 ↗ |
| 2026-05-07 | 2026-05-01 | Rodriguez Javier See Remarks | MExercise | +9.00K | — | — | No | Form 4 ↗ |
| 2026-03-16 | 2026-03-15 | Mehta Vimal CEO and President | MExercise | +219.00 | — | — | No | Form 4 ↗ |
| 2026-03-16 | 2026-03-15 | Steinhart Richard I Chief Financial Officer | MExercise | +35.00 | — | — | No | Form 4 ↗ |
| 2026-03-16 | 2026-03-15 | Rodriguez Javier See Remarks | MExercise | +35.00 | — | — | No | Form 4 ↗ |
| 2026-03-16 | 2026-03-15 | Yocca Frank Chief Scientific Officer | MExercise | +35.00 | — | — | No | Form 4 ↗ |
| 2026-03-16 | 2026-03-14 | Mehta Vimal CEO and President | MExercise | +164.00 | — | — | No | Form 4 ↗ |
| 2026-03-16 | 2026-03-14 | Steinhart Richard I Chief Financial Officer | MExercise | +33.00 | — | — | No | Form 4 ↗ |
| 2026-03-16 | 2026-03-14 | Rodriguez Javier See Remarks | MExercise | +33.00 | — | — | No | Form 4 ↗ |
| 2026-03-16 | 2026-03-14 | Yocca Frank Chief Scientific Officer | MExercise | +33.00 | — | — | No | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also BTAI’s full analysis or the market-wide insider trading feed. The tabs above jump to BTAI’s other SEC data.
Source: SEC Form 4 filings for BTAI, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.